Hengrui's HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis
CompanyDrug

Hengrui’s HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis

IASO Bio's In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL
CompanyDrug

IASO Bio’s In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL

Chia Tai Tianqing's Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval
CompanyDrug

Chia Tai Tianqing’s Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval

CSPC's SYS6010 Granted NMPA Breakthrough Therapy Designation – EGFR‑Targeting ADC for Refractory Non‑Squamous NSCLC
CompanyDrug

CSPC’s SYS6010 Granted NMPA Breakthrough Therapy Designation – EGFR‑Targeting ADC for Refractory Non‑Squamous NSCLC

Gilead and PAHO Sign Agreement to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean
CompanyDeals

Gilead and PAHO Sign Agreement to Expand Twice-Yearly Lenacapavir PrEP Access Across Latin America and the Caribbean

China's NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies
Policy / Regulatory

China’s NHSA Pilots Pre-Project Approval System for Medical Service Pricing – Fast Lane for Innovative Technologies

GenEditBio's GEB-101 Granted FDA Fast Track Designation – First‑in‑Class Genome‑Editing Therapy for TGFBI Corneal Dystrophies
CompanyDrug

GenEditBio’s GEB-101 Granted FDA Fast Track Designation – First‑in‑Class Genome‑Editing Therapy for TGFBI Corneal Dystrophies

CBMG Wins FDA Clearance for C-CAR168 Phase Ib/II Trial – Bispecific CAR‑T Targets Progressive Multiple Sclerosis
CompanyDrug

CBMG Wins FDA Clearance for C-CAR168 Phase Ib/II Trial – Bispecific CAR‑T Targets Progressive Multiple Sclerosis

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease
CompanyDeals

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease

NMPA Issues Medical Device GMP Inspection Guidelines – Revised Production Quality Standards Take Effect November 1, 2026
Medical DevicePolicy / Regulatory

NMPA Issues Medical Device GMP Inspection Guidelines – Revised Production Quality Standards Take Effect November 1, 2026

Hengrui Pharma's Recaticimab Cleared by NMPA for Phase 3 Trial – Targeting Stroke Recurrence in Intracranial Atherosclerotic Stenosis
CompanyDrug

Hengrui Pharma’s Recaticimab Cleared by NMPA for Phase 3 Trial – Targeting Stroke Recurrence in Intracranial Atherosclerotic Stenosis

FDA Approves Imdelltra Label Update – Monitoring Time for First Two Doses Cut to 6–8 Hours from 22–24, Easing Delivery of Amgen's First‑in‑Class SCLC Immunotherapy
CompanyDrug

FDA Approves Imdelltra Label Update – Monitoring Time for First Two Doses Cut to 6–8 Hours from 22–24, Easing Delivery of Amgen’s First‑in‑Class SCLC Immunotherapy